The schematics showed that orally consumed flavanols are converted by GI microbiota into phenolic acid metabolites, some of which are biologically available in the plasma and/or the brain. Highlighted are effects of plasma-accumulating DHCA in the modulating inflammation and brain-accumulating 3-HBA, 3,4-diHBA, and 3-HPPA in inhibiting with protein folding, and that both anti-inflammation and protein-misfolding activities of these biologically available, bioactive phenolic acid metabolites would promote resilience for a diverse neurological disorders for which inflammation and misfolding are significant pathological processes. The implication of this overview is that interpersonal differences in GI microbiota would affect generation and thereby bioavailability of bioactive phenolic acid metabolites, would differentially affect the efficacy of dietary flavanols on the modulation of neurological resilience of diverse neurological disorders involving inflammation and/or protein misfolding.